Moleculin Biotech Files 8-K on Financials
Ticker: MBRX · Form: 8-K · Filed: Mar 24, 2025 · CIK: 1659617
| Field | Detail |
|---|---|
| Company | Moleculin Biotech, Inc. (MBRX) |
| Form Type | 8-K |
| Filed Date | Mar 24, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Moleculin Biotech dropped its 8-K with financial updates on March 24, 2025.
AI Summary
Moleculin Biotech, Inc. filed an 8-K on March 24, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the earliest event reported as of March 24, 2025. The company is incorporated in Delaware and headquartered in Houston, Texas.
Why It Matters
This filing provides investors with updated financial information and operational details for Moleculin Biotech, Inc., crucial for assessing the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Moleculin Biotech, Inc. (company) — Registrant
- March 24, 2025 (date) — Date of earliest event reported
- 5300 Memorial Drive, Suite 950, Houston, TX 77007 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Moleculin Biotech, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was as of March 24, 2025.
What is Moleculin Biotech, Inc.'s state of incorporation?
Moleculin Biotech, Inc. is incorporated in Delaware.
Where are Moleculin Biotech, Inc.'s principal executive offices located?
Moleculin Biotech, Inc.'s principal executive offices are located at 5300 Memorial Drive, Suite 950, Houston, TX 77007.
What is the company's telephone number?
The company's telephone number is (713) 300-5160.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 24, 2025 regarding Moleculin Biotech, Inc. (MBRX).